Intelligence Feed event · Equity · 2026-10-13

    Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth Outlook

    Question

    Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth Outlook

    Direct answer

    Abbott Laboratories advanced 2.23% to $101.82, outpacing the S&P 500's 0.06% daily dip. The company is set to report third-quarter earnings on October 21, 2026, where consensus forecasts project a 9.23% year-over-year increase in EPS to $1.42 and a 13.52% expansion in revenue to $12.91 billion. AbbVie rose 1.65% to $281.04, building on a 7.53% one-month gain. Analysts project AbbVie's October 30 earnings release to reflect a 104.3% surge in EPS alongside a 10.01% top-line increase, providing fundamental support to the large-cap pharmaceutical complex.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-13
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth Outlook”, revision 1, evidence through 2026-10-13. https://marketontology.com/market-events/2026-10-13/abbott-and-abbvie-gain-over-1-6-outperforming-s-p-on-strong-q3-growth-outlook-4d934e

    EQUITY
    Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth Outlook
    Abbott Laboratories advanced 2.23% to $101.82, outpacing the S&P 500's 0.06% daily dip. The company is set to report third-quarter earnings on October 21, 2026, where consensus forecasts project a 9.23% year-over-year increase in EPS to $1.42 and a 13.52% expansion in revenue to $12.91 billion. AbbVie rose 1.65% to $281.04, building on a 7.53% one-month gain. Analysts project AbbVie's October 30 earnings release to reflect a 104.3% surge in EPS alongside a 10.01% top-line increase, providing fundamental support to the large-cap pharmaceutical complex.
    ABTABBV
    Impact
    68
    OCT 13
    SIG
    85%
    ABTABBV
    Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth Outlook
    Abbott Laboratories advanced 2.23% to $101.82, outpacing the S&P 500's 0.06% daily dip. The company is set to report third-quarter earnings on October 21, 2026, where consensus forecasts project a 9.23% year-over-year increase in EPS to $1.42 and a 13.52% expansion in revenue to $12.91 billion. AbbVie rose 1.65% to $281.04, building on a 7.53% one-month gain. Analysts project AbbVie's October 30 earnings release to reflect a 104.3% surge in EPS alongside a 10.01% top-line increase, providing fundamental support to the large-cap pharmaceutical complex.
    → Anticipated double-digit top-line growth at Abbott ($12.91B, +13.52%) and AbbVie (+10.01%) drives defensive healthcare multiple expansion during broad equity consolidation.
    Impact
    Abbott Laboratories advanced 2.23% to $101.82, outpacing the S&P 500's 0.06% daily dip. The company is set to report third-quarter earnings on October 21, 2026, where consensus forecasts project a 9.23% year-over-year increase in EPS to $1.42 and a 13.52% expansion in revenue to $12.91 billion. AbbVie rose 1.65% to $281.04, building on a 7.53% one-month gain. Analysts project AbbVie's October 30 earnings release to reflect a 104.3% surge in EPS alongside a 10.01% top-line increase, providing fundamental support to the large-cap pharmaceutical complex.
    Affected
    ABTABBV
    Transmission
    Anticipated double-digit top-line growth at Abbott ($12.91B, +13.52%) and AbbVie (+10.01%) drives defensive healthcare multiple expansion during broad equity consolidation.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ABTearnings revision momentum ahead of October 21 printUp1-4wABT gained 2.23% to $101.82 with Q3 revenue projected up 13.52% YoY.
    ABBVearnings multiple expansion on 104.3% projected EPS growthUp1-4wABBV rose 1.65% to $281.04 with Q3 earnings scheduled for October 30.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month